Cv3 - Cost-Effectiveness of Sacubitril/Valsartan in Germany: Applying the Efficiency Threshold

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.034
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Cost-Effectiveness of Sacubitril/Valsartan in the Treatment of Heart Failure in Colombia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction: Cost and Effectiveness in the Italian Context

European Journal of Heart Failure
Cardiovascular MedicineCardiology
2017English

Pcv82 - Cost-Effectiveness of Sacubitril/Valsartan in the Treatment of Heart Failure With Reduced Ejection Fraction in Singapore

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcv86 - Cost-Effectiveness of Sacubitril/Valsartan in the Treatment of Heart Failure Under the Brazilian Private Healthcare System Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Sacubitril/Valsartan Use for the Hospitalist

American Journal of Hospital Medicine
2017English

Pcv71 - Cost-Effectiveness of Sacubitril/Valsartan for the Treatment of Symptomatic Chronic Heart Failure With Reduced Ejection Fraction in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Potential Markers of Sacubitril-Valsartan Tolerance

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Sacubitril/Valsartan: Beyond Natriuretic Peptides

Heart
Cardiovascular MedicineCardiology
2017English

Sacubitril-Valsartan in Heart Failure and Multimorbidity Patients

ESC heart failure
Cardiovascular MedicineCardiology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy